1. In Vivo
  2. >>Archive

Intrexon Buys Tools, Wins Partners

 
• By Melanie Senior

Intrexon’s acquisitions since mid-2014 have given it a shot at solving some high-profile challenges, and have attracted mainstream pharmaceutical partners.

Intrexon Corp.’s own tools might not have become industry standards. But the company’s half a dozen acquisitions since mid-2014 have given it a shot at solving some high-profile challenges, and have attracted mainstream pharmaceutical partners.

Cattle breeding and genetics platform Trans Ova, acquired in mid-2014, now accounts for about half of Intrexon’s revenues. Buying UK-based Oxitec Ltd. in August 2015 pushed Intrexon into the spotlight...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

US Health System Redesign Critical, NAM’s Medical Experts Warn Trump Government

 
• By Ashley Yeo

The whirlwind back-and-forth on US tariffs and Robert F. Kennedy jr.’s plans to deregulate health care have become all-preoccupying, but the National Academy of Medicine was first to set out President Trump’s health administration priorities.

Podcast: “Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

 
• By Anabel Costa-Ferreira

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.

ML-Assisted Genetic Risk Score Predicts GLP-1 Adverse Events

 
• By David Wild

Phenomix Science presented new data at Digestive Disease Week 2025 showing its machine learning-assisted genetic risk score can predict nausea and side effects from GLP-1 receptor agonists, aiding personalized obesity treatment.